Biological characteristics and treatment outcomes of metastatic or recurrent neuroendocrine tumors: tumor grade and metastatic site are important for treatment strategy
about
Phase 2 study of everolimus monotherapy in patients with nonfunctioning neuroendocrine tumors or pheochromocytomas/paragangliomas.Diagnosis and prediction of neuroendocrine liver metastases: a protocol of six systematic reviews.Treatment of liver metastases in patients with neuroendocrine tumors: a comprehensive review.Clinicopathological analysis in patients with neuroendocrine tumors that metastasized to the brain.The expanding role of somatostatin analogs in the management of neuroendocrine tumors.Long-term management of a patient with well-differentiated pulmonary neuroendocrine carcinoma: a case reportAssessment of intracranial metastases from neuroendocrine tumors/carcinoma.Pancreatic neuroendocrine tumors: biology, diagnosis,and treatmentThe expanding role of somatostatin analogs in gastroenteropancreatic and lung neuroendocrine tumors.Radionuclide Therapy for Neuroendocrine Tumors.Elevated Alkaline Phosphatase Prior to Transarterial Chemoembolization for Neuroendocrine Tumors Predicts Worse Outcomes.Incidental metastatic mediastinal atypical carcinoid in a patient with parathyroid adenoma: a case reportInternational Union of Basic and Clinical Pharmacology. CV. Somatostatin Receptors: Structure, Function, Ligands, and New Nomenclature
P2860
Q33401986-1F633459-AEB8-4523-9A2C-7BD184220AD4Q35074944-1E6E3F78-F82F-41B6-817C-9E48B63ABA39Q35371197-812EE679-7E01-4FD1-995C-2B0A130B5CCCQ35902109-77A1FDC2-75B4-4DE5-A0A5-F433C9D676CDQ36347272-C987C3A3-2622-43EC-A4F6-3C4E6FBEEFE8Q36797100-D40DFD3F-060B-4E7F-8C66-A40C49C9E9ECQ36981394-0AA91CA0-D610-4227-AA07-6039CE3BB317Q37354131-08849FB4-30AF-4E12-819D-D15BCAC48D87Q38441413-74A07255-45C6-4AC2-9B25-11916ADF79C3Q39144880-56DEE516-0E67-41A6-A592-DA3DF1C8A286Q41196104-F5E96270-4A99-44F1-A41C-AC055F1DB15BQ42314339-958BFC42-7332-4384-BA99-22F18C5BA0C5Q57144951-E5ED98A5-2866-4974-B847-99C442402AB3
P2860
Biological characteristics and treatment outcomes of metastatic or recurrent neuroendocrine tumors: tumor grade and metastatic site are important for treatment strategy
description
2010 nî lūn-bûn
@nan
2010 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Biological characteristics and ...... portant for treatment strategy
@ast
Biological characteristics and ...... portant for treatment strategy
@en
type
label
Biological characteristics and ...... portant for treatment strategy
@ast
Biological characteristics and ...... portant for treatment strategy
@en
prefLabel
Biological characteristics and ...... portant for treatment strategy
@ast
Biological characteristics and ...... portant for treatment strategy
@en
P2093
P2860
P356
P1433
P1476
Biological characteristics and ...... portant for treatment strategy
@en
P2093
Dae Seog Heo
Do-Youn Oh
Dong-Wan Kim
Jin Won Kim
Sae-Won Han
Se-Hoon Lee
Seock-Ah Im
Su-Jung Kim
Tae-You Kim
Yung-Jue Bang
P2860
P2888
P356
10.1186/1471-2407-10-448
P407
P577
2010-08-23T00:00:00Z
P5875
P6179
1036359049